Before joining Onxeo, Dr. Shefali Agarwal was Chief Medical Officer at Epizyme, Inc., a clinical-stage company developing novel epigenetic therapies for cancer and other serious diseases, where she leads the global clinical development and regulatory strategy for tazemetostat for the treatment of cancer. Prior to joining Epizyme in 2018, Dr. Agarwal held leadership positions across medical research, clinical development, clinical operations and medical affairs. She most recently served as chief medical officer at SQZ Biotech, where she built and led the clinical development organization, which included clinical research operations and the regulatory function. Before SQZ Biotech, Dr. Agarwal also held leadership positions at Curis and Tesaro. At Curis, she oversaw the Phase 2 study for its dual HDAC/PI3K inhibitor in diffuse large B-cell lymphoma, and the Phase 1 study in solid tumors for its oral checkpoint inhibitor. At Tesaro, she led the NDA and EMA submissions for ZEJULA(r) (niraparib) in ovarian cancer. Dr. Agarwal has also held positions of increasing responsibility at Covidien, AVEO Oncology and Pfizer. In addition to receiving her medical degree, Dr. Agarwal holds a master’s of public health and a master’s of science in business.

He began his career as Deputy Chief Financial Officer at Total in Cameroon in 1990 and then as Financial Auditor at Ernst & Young on various missions in the industrial and financial sectors.

He then moved to the pharmaceutical industry where, from 1996 to 2006, he held positions of increasing responsibility within the finance division of Pfizer France: first in charge of the treasury and internal audit as Director of Treasury, Tax and Audit. In this position, he was responsible in particular for financial risk management for the French subsidiaries of Pfizer and he managed the financial implementation of various restructuring operations (including two mergers, one with Warner-Lambert in 2000 and then Pharmacia in 2003) as well as the implementation of tax and financial optimisation schemes.
Nicolas Fellmann is a graduate of Lyon Graduate School of Management (EM Lyon).

Since 2005, Olivier de Beaumont was with Stallergenes Greer as Senior Vice President, Head of Global Clinical Development, Pharmacovigilance and Medical Affairs, and a member of the Executive Committee. Prior to that, he led various clinical development programs and strategic marketing activities at Quintiles and Aventis, addressing a wide range of therapeutic areas and leading teams, notably in oncology. Dr. de Beaumont is a medical doctor and also holds a MBA from ESCP Business School and a Masters degree in Public Health & Health Economics.

Audrey Legentil-Duméry worked as a Senior HR consultant with a Paris-based agency, managing HR on behalf of diverse companies, notably accompanying SME’s through periods of growth and transition.

Ms. Legentil-Duméry successfully conducted several missions in the pharma and biotech sectors.

Audrey Legentil-Duméry holds a Magister and a Master in Management and Intercultural Communication from CELSA (Sorbonne, Paris).